Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €7.84 EUR
Change Today -0.026 / -0.33%
Volume 3.5K
APS On Other Exchanges
As of 1:21 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (APS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - €8.65
52 Week Low
07/18/14 - €3.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ariad pharmaceuticals inc (APS) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (APS) Details

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

379 Employees
Last Reported Date: 03/2/15
Founded in 1991

ariad pharmaceuticals inc (APS) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $749.8K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $465.4K
President of Research & Development and Chief...
Total Annual Compensation: $492.4K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $427.3K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $386.4K
Compensation as of Fiscal Year 2013.

ariad pharmaceuticals inc (APS) Key Developments

Ariad Pharmaceuticals Inc. Receives Approval for Iclusig® (Ponatinib) from Israeli Ministry of Health

Ariad Pharmaceuticals Inc. announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig® (ponatinib) in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation; Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of Iclusig is expected to occur in the second quarter of 2015. The Ministry of Health decision was based on results from the pivotal Phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial in patients with CML or Ph+ ALL who were resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy, or who had the T315I mutation of BCR-ABL. Iclusig demonstrated anti-leukemic activity achieving a major cytogenetic response (MCyR) in 54% of chronic-phase CML patients and in 70% of patients with the T315I mutation. MCyR within the first 12 months was the primary endpoint of the PACE trial for chronic-phase patients. In patients with advanced disease, 57% of accelerated-phase CML patients and 34% of blast-phase CML patients achieved a major hematologic response (MaHR) with Iclusig. MaHR within the first 6 months was the primary endpoint in the trial for patients with advanced disease.

ARIAD Pharmaceuticals, Inc. Announces Dismissal of Shareholder Derivative Lawsuit in Federal District Court

ARIAD Pharmaceuticals Inc. announced that the United States District Court for the District of Massachusetts dismissed the shareholder derivative lawsuit filed in late 2013 against the company and certain of its officers and directors in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig® (ponatinib) on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy. The suit alleged breach of fiduciary duty, misappropriation of confidential information and insider trading. The Court granted the company's motion to dismiss the lawsuit, concluding that the plaintiffs failed to make a demand of the company's board of directors to investigate the allegations as required by Delaware law, the state where the company is incorporated, and also failed to allege sufficient facts to excuse that demand.

Ariad Pharmaceuticals Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Financial Guidance for 2015

Ariad Pharmaceuticals Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss for the fourth quarter ended December 31, 2014 was $5.7 million, or $0.03 per share, compared to a net loss of $74.2 million, or $0.40 per share, for the same period in 2013. The decrease in net loss is primarily due to the $50 million received from Bellicum in the fourth quarter of 2014, an increase of $13.2 million in Iclusig product revenue and a decrease in operating expenses of $8.0 million, reflecting lower research and development (R&D) expenses, offset in part by an increase in interest expense of $3.8 million due to its convertible debt issuance in June 2014. Net product revenues from sales of Iclusig were $21.4 million for the quarter ended December 31, 2014 and $55.7 million for the year ended December 31, 2014. Net product revenues for the fourth quarter include Iclusig revenues of $17.0 million in the U.S. and $4.4 million in Europe. Net product revenues in the fourth quarter represented a 47% increase from the prior quarter. For the year, the company reported net loss for the full year 2014 was $162.6 million, or $0.87 per share, compared to a net loss of $274.2 million, or $1.49 per share, for the full year 2013. For 2015, the company expected net product revenues from sales of Iclusig are expected to be in the range of $130 million to $140 million. R&D expenses are expected to be in the range of $185 million to $195 million, reflecting increased development activities for Iclusig, brigatinib, and AP32788, as well as ongoing discovery research efforts. Cash and cash equivalents at December 31, 2015 is expected to be at least $200 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APS:GR €7.84 EUR -0.026

APS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.37 USD -0.11
Array BioPharma Inc $7.37 USD -0.17
Evotec AG €3.75 EUR -0.07
Insys Therapeutics Inc $58.13 USD +1.08
Pfizer Ltd/India 2,230 INR +24.30
View Industry Companies

Industry Analysis


Industry Average

Valuation APS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.2x
Price/Book 19.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at